There are currently 14 clinical trials in North Canton, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Neuro-Behavioral Clinical Research, Inc. and Neuro-Behavioral Clinical Research. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
NCT06268886
Recruiting
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Gender:
ALL
Ages:
Between 60 years and 80 years
Trial Updated:
01/23/2025
Locations: Local Institution - 0216, North Canton, Ohio
Conditions: Alzheimer Disease, Early Onset
Register for Updates
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242
Recruiting
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
01/23/2025
Locations: Neuro-Behavioral Clinical Research, Inc., North Canton, Ohio
Conditions: Pediatric Migraine
Register for Updates
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
NCT05729373
Recruiting
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/23/2025
Locations: Research Site #115, North Canton, Ohio
Conditions: Generalized Anxiety Disorder
Register for Updates
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
NCT06413433
Recruiting
ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of binge eating disorder (BED) in adults.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/21/2025
Locations: Clinical Research Site, North Canton, Ohio
Conditions: Binge-Eating Disorder
Register for Updates
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
NCT04624659
Recruiting
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
01/20/2025
Locations: Neuro-Behavioral Clinical Research, North Canton, Ohio
Conditions: Sickle Cell Disease
Register for Updates
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
NCT05443724
Recruiting
The primary purpose of this study is to assess the long-term safety and tolerability of oral emraclidine in adult participants with schizophrenia.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/10/2025
Locations: North Canton, Ohio, North Canton, Ohio
Conditions: Schizophrenia
Register for Updates
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
NCT06058013
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/10/2025
Locations: Neumora Investigator Site, North Canton, Ohio
Conditions: Major Depressive Disorder
Register for Updates
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease
NCT05644977
Recruiting
The primary purpose of the study is to evaluate the safety and tolerability of emraclidine administered orally to healthy elderly participants in Part A (multiple ascending doses) and participants with dementia due to Alzheimer's disease (AD) in Part B.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
01/09/2025
Locations: North Canton, Ohio, North Canton, Ohio
Conditions: Healthy Participants, Alzheimer's Disease Dementia
Register for Updates
A Study of CLE-100 (oral Esketamine) As an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder
NCT06340958
Recruiting
The study is a Phase 2, double-blind, randomized, placebo-controlled study in Major Depressive Disorder (MDD) participants with an inadequate response to standard antidepressants The objective of the study is to assess CLE-100 (oral esketamine) for the treatment of MDD in participants currently treated with an oral antidepressant medication and who have an inadequate response to at least 2 antidepressants.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/24/2024
Locations: Clinical Site 119, North Canton, Ohio
Conditions: Adjunctive Treatment of Major Depressive Disorder (MDD)
Register for Updates
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
NCT06079190
Recruiting
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment \[MCI\] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
12/04/2024
Locations: GSK Investigational Site, North Canton, Ohio
Conditions: Alzheimer's Disease
Register for Updates
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
NCT05624268
Recruiting
Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: Neuro-Behaviroral Clinical Research, Inc., North Canton, Ohio
Conditions: Treatment Resistant Depression
Register for Updates
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
NCT06480383
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: Clinical Site, North Canton, Ohio
Conditions: Generalized Anxiety Disorder
Register for Updates